In conclusion, it was revealed that aberrant miR-330-3p expression could increase ER+ BC resistance to tamoxifen, that miR-330-3p levels reversely correlate with HDAC4 in ER+ BC cells, and that miR-330-3p induces TR in an HDAC4-dependent manner. The gene discussed is ESR1; the disease is breast cancer.